COMMUNIQUÉS West-GlobeNewswire

Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
14/08/2026
Call scheduled for today, Friday, August 14, 2026, at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 [...]
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
14/08/2026
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional [...]
Vaso Corporation Announces Financial Results for Second Quarter of 2026
14/08/2026
PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive medical [...]
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
14/08/2026
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution [...]
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
14/08/2026
– Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company’s business transformation – – Trinity Biotech [...]
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
14/08/2026
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor [...]
Tennessee Donor Services Honors Local Donor Heroes During National Multicultural Donor Awareness Month
14/08/2026
NASHVILLE, Tenn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- During the month of August, Tennessee Donor Services and Donate Life Tennessee recognize National Multicultural Donor Awareness Month by honoring the diverse donor [...]
CERTIFIED Brand Debuts in Reynoldsburg, Expanding Access to East Columbus Communities
14/08/2026
Ohio-born cannabis company's products and experience now available at new East Livingston Avenue dispensary in Reynoldsburg REYNOLDSBURG, Ohio, Aug. 14, 2026 (GLOBE NEWSWIRE) -- CERTIFIED , a family-owned, vertically [...]
ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system
14/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX ® ) and house dust mite tablet ( [...]
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026 Successfully completed [...]
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
14/08/2026
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed [...]
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in [...]
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
14/08/2026
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations Announced [...]
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
14/08/2026
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference New clinical data for bizaxofusp, used for the treatment of unresectable recurrent IDH-WT [...]
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
14/08/2026
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway [...]
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
14/08/2026
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including [...]
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
14/08/2026
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 [...]
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
14/08/2026
- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“ [...]

Pages